Next-Generation Facilities for Monoclonal Antibody Production - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Next-Generation Facilities for Monoclonal Antibody Production
Dramatic increases in yields from cell lines and the increasing popularity of single-use technologies will change the way we look at future bioprocessing facilities and process designs.

Pharmaceutical Technology
Volume 33, Issue 7, pp. 68-73

Dispruptive technology

Manufacturers of future high-titer mAbs will have the option of using traditional stainless-steel equipment, single-use equipment, or a hybrid combination of the two. Availability of single-use bioreactors with working volumes of 1000–2000 L makes them a compelling alternative as a production platform. In reality, the important issue is not stainless steel or single-use technology, but rather how technologies can be combined to provide the most productive and cost-effective process. Choosing one or the other technology concept depends on both strategic considerations and feasibility studies of each individual case.

Stainless steel. A stainless-steel manufacturing facility for biotechnology products is based on well-known design principles originating from the petrochemical and dairy industries, with additional considerations for cross-contamination prevention and sterility. The facility is characterized by having a fixed piping and tank layout (mobile vessels are possible below the 1000-L scale). Once the investment is made and the installation is finalized, the strategic safety of having all process equipment in-house is obtained. Only a few dependencies for consumables and spare parts remain.

Stainless-steel technology is well suited for automation applied to improve safety, ergonomics, process reproducibility, and to reduce training scope. Because instrumentation for cleaning and sterilization does not contribute directly to the production process, the technology carries some overhead and requires significant maintenance and validation. Cleaning stations for utensils and mobile tanks add to the complexity.

Single-use. Compared with stainless steel, single-use technology has obvious advantages, primarily a reduced investment cost and an inherent elimination of risk from cross-contamination because the product-contacting surface is disposed of after each batch. Piping between process steps may be eliminated with plastic tubing and manual transport to move bag containers between process stations. Working volumes as much as 3000 L for simple solution hold are available. Bioreactors with capacities as high as 2000 L have been proven suitable for running many processes.

Being highly flexible, single-use technology can be reconfigured for a new process or product in a few days. Another important feature is that installation is simplified because of a reduced need for cleaning and sterilization, which again translates into reduced capacities for clean steam, clean-in-place, and waste collection and treatment.

Still, there are a number of challenges for single-use technology. The technology is less orderly, so the arrangement of tubing must not interfere with operator activities, and process accuracy must be considered. The technology has limitations for demanding mixing and heat-transfer applications. Large-range reliable single use sensors are just starting to become available.

The complexity of single-use technology is that the core process-contacting elements are essentially built up again for each batch so instruction and training demands become more important factors. The flexible and more manual nature of processing is also reflected in increased material handling and tracking challenges. For critical components, a dual-vendor strategy is desirable but not always possible because not all single-use inserts will fit all supports or racks to hold them.

Feasibility considerations. Estimating the economic prospects of single-use technology can be done with feasibility studies, which typically can be simplified if specific cost of goods values are not required. It is important to consider the entire production scenario before simplifications are made. In many cases, not including high batch-frequency operations, single-use technology is a more favorable concept. Such is the case with respect to investment cost but also with respect to variable costs when the cost of the capital that would otherwise go into the investment of the comparable stainless-steel operation is included. Amortization and interest of stainless equipment over time must be added to variable costs, and many case studies will show that it exceeds variable cost related to increased consumables for a single-use design.

Assumptions regarding the cost of cleaning chemicals and water for injection are often included in feasibility studies but are seldom the deciding factor, because the cost is usually low compared with other consumables and cost of capital. It is important to use cost data that reflect the scale of operation. Sometimes, estimates about reductions in operator time are introduced in to the feasibility study. Although personnel costs are important, such estimates can be difficult to realize in real life. It is a more conservative approach to state that operators may be freed up to improve process operation and monitoring instead of handling cleaning processes.

Designing the next-generation facility

A new facility design paradigm arises from the combination of high-titer processes and single-use technology. Jagschies has addressed the question of realistic estimates for future mAb product volumes (8). The viewpoint is that most products will require less than 500 kg annually capacity with few products requiring as much as 1000 kg. Assuming 5 g/L titer and typical process conditions places an annual output of 1000 kg within the reach of a facility based on six bioreactors with 2000-L working volume. Not surprisingly, the 10+ fold yield increase over the titers from earlier times is reflected in a facility housing significantly smaller bioreactors, thus paving the way for an upstream process based on single-use technology instead of traditional stainless-steel technology.

Figure 2
Figure 2 illustrates the conceptual differences between the traditional and the next-generation facility. The three-dimensional model shows typical equipment simplistically lined up to compare floor space and room height between a traditional 6 20,000 L bioreactor facility and a single-use 6 2000 L bioreactor facility. The scenario illustrates that the next-generation facility will exhibit both a reduced footprint and reduced building complexity by being able to fit into a one production-level facility, because the bioreactors will not protrude through several levels.

This design would require in-line dilution of concentrated buffers and potentially a series of product pool bags for downstream processing of the large product volumes arising from the individual bioreactor. Depending on production strategy, the volumes involved also open up for supply of ready-made media and buffers. Therefore, the media and buffer preparation suites may be eliminated from the facility or reduced significantly.

Compared with the traditional mAb facility, next-generation single-use facilities will be more generalized with a series of process stations where utilities are presented and process equipment can be hooked up to form the required process. There will be an added emphasis on logistics and workflows, resulting from changed requirements for storage, manual transport of process liquids, and equipment, waste, and personnel flows.

Life in the next-generation facility

Automating single-use technology. In changing from stainless-steel to single-use operation, manufacturers may lose aspects of the orderly process hook up and the easy tracking of when actions and process events happened, when operators intervened, and when valves (clamps in the single-use case) were opened and closed.

Figure 3
As it stands, the state of the art for single-use technology, written procedures and training are the cornerstones to ensuring the process remains reproducible. In this capacity, automation enables technology to create a type of comfort zone around the low-automation level process step (see Figure 3).

As facilities go from pilot plant-scale to full-production scale, the industry will see automation strategies in which the process itself is handled by the vendor-supplied local control and a central manufacturing execution system (MES) forms a process support system guiding the operator through all steps necessary for the process (see Figure 3). Tracking and material-handling technologies such as barcode systems are already available to ensure good housekeeping for materials, equipment, and new and used consumables. The most recent development is that single-use items are also available with RFID tags.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here